New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Latest News

7 hours	Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 EXEL Business Wire
10 hours	Exelixis (EXEL) Loses 12% on Cancer Treatment Trial Results EXEL Insider Monkey
12 hours	ALKS vs. RGEN: Which Stock Is the Better Value Option? ALKS Zacks
13 hours	Wall Street Analysts Predict a 34.8% Upside in Alkermes (ALKS): Here's What You Should Know ALKS Zacks
14 hours	Is Alkermes (ALKS) Stock Undervalued Right Now? ALKS Zacks
14 hours	Are Medical Stocks Lagging Alkermes (ALKS) This Year? ALKS Zacks
14 hours	Goldman downgraded, Coinbase initiated: Wall Street's top analyst calls EXEL The Fly
Oct-20	H.C. Wainwright Remains Bullish on Immunocore Holdings plc (IMCR) IMCR Insider Monkey
Oct-20	Alkermes to Report Third Quarter Financial Results on October 28, 2025 ALKS PR Newswire
Oct-20	Exelixis shares dip on colorectal cancer data EXEL BioPharma Dive
Oct-20	Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet EXEL Business Wire
Oct-18	Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 EXEL Business Wire
Oct-17	Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis KNSA GlobeNewswire
Oct-16	Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again KNSA Zacks
Oct-14	Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet KNSA Zacks

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.